These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35158929)

  • 1. Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia.
    Forconi F; Lanham SA; Chiodin G
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status.
    Mockridge CI; Potter KN; Wheatley I; Neville LA; Packham G; Stevenson FK
    Blood; 2007 May; 109(10):4424-31. PubMed ID: 17255355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL.
    D'Avola A; Drennan S; Tracy I; Henderson I; Chiecchio L; Larrayoz M; Rose-Zerilli M; Strefford J; Plass C; Johnson PW; Steele AJ; Packham G; Stevenson FK; Oakes CC; Forconi F
    Blood; 2016 Aug; 128(6):816-26. PubMed ID: 27301861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL.
    Chiodin G; Drennan S; Martino EA; Ondrisova L; Henderson I; Del Rio L; Tracy I; D'Avola A; Parker H; Bonfiglio S; Scarfò L; Sutton LA; Strefford JC; Forster J; Brake O; Potter KN; Sale B; Lanham S; Mraz M; Ghia P; Stevenson FK; Forconi F
    Blood Adv; 2022 Sep; 6(18):5494-5504. PubMed ID: 35640238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.
    Guo A; Lu P; Galanina N; Nabhan C; Smith SM; Coleman M; Wang YL
    Oncotarget; 2016 Jan; 7(4):4598-610. PubMed ID: 26717038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.
    Krysov S; Steele AJ; Coelho V; Linley A; Sanchez Hidalgo M; Carter M; Potter KN; Kennedy B; Duncombe AS; Ashton-Key M; Forconi F; Stevenson FK; Packham G
    Blood; 2014 Nov; 124(20):3101-9. PubMed ID: 25170122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients.
    Drennan S; Chiodin G; D'Avola A; Tracy I; Johnson PW; Trentin L; Steele AJ; Packham G; Stevenson FK; Forconi F
    Clin Cancer Res; 2019 Apr; 25(8):2503-2512. PubMed ID: 30373751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-4 enhances expression and function of surface IgM in CLL cells.
    Aguilar-Hernandez MM; Blunt MD; Dobson R; Yeomans A; Thirdborough S; Larrayoz M; Smith LD; Linley A; Strefford JC; Davies A; Johnson PM; Savelyeva N; Cragg MS; Forconi F; Packham G; Stevenson FK; Steele AJ
    Blood; 2016 Jun; 127(24):3015-25. PubMed ID: 27002119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spatial organization and early signaling of the B-cell receptor in CLL.
    Shorer Arbel Y; Bronstein Y; Dadosh T; Kamdjou T; Tsuriel S; Shapiro M; Katz BZ; Herishanu Y
    Front Immunol; 2022; 13():953660. PubMed ID: 36016925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-4 rescues surface IgM expression in chronic lymphocytic leukemia.
    Guo B; Zhang L; Chiorazzi N; Rothstein TL
    Blood; 2016 Jul; 128(4):553-62. PubMed ID: 27226435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study.
    Bomben R; Dal Bo M; Capello D; Forconi F; Maffei R; Laurenti L; Rossi D; Del Principe MI; Zucchetto A; Bertoni F; Rossi FM; Bulian P; Cattarossi I; Ilariucci F; Sozzi E; Spina V; Zucca E; Degan M; Lauria F; Del Poeta G; Efremov DG; Marasca R; Gaidano G; Gattei V
    Br J Haematol; 2009 Feb; 144(4):492-506. PubMed ID: 19036101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Number of Overlapping AID Hotspots in Germline IGHV Genes Is Inversely Correlated with Mutation Frequency in Chronic Lymphocytic Leukemia.
    Yuan C; Chu CC; Yan XJ; Bagnara D; Chiorazzi N; MacCarthy T
    PLoS One; 2017; 12(1):e0167602. PubMed ID: 28125682
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Maity PC; Bilal M; Koning MT; Young M; van Bergen CAM; Renna V; Nicolò A; Datta M; Gentner-Göbel E; Barendse RS; Somers SF; de Groen RAL; Vermaat JSP; Steinbrecher D; Schneider C; Tausch E; Bittolo T; Bomben R; Mazzarello AN; Del Poeta G; Kroes WGM; van Wezel JT; Imkeller K; Busse CE; Degano M; Bakchoul T; Schulz AR; Mei H; Ghia P; Kotta K; Stamatopoulos K; Wardemann H; Zucchetto A; Chiorazzi N; Gattei V; Stilgenbauer S; Veelken H; Jumaa H
    Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4320-4327. PubMed ID: 32047037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
    Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell receptor signaling in chronic lymphocytic leukemia.
    Stevenson FK; Krysov S; Davies AJ; Steele AJ; Packham G
    Blood; 2011 Oct; 118(16):4313-20. PubMed ID: 21816833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.
    Blunt MD; Koehrer S; Dobson RC; Larrayoz M; Wilmore S; Hayman A; Parnell J; Smith LD; Davies A; Johnson PWM; Conley PB; Pandey A; Strefford JC; Stevenson FK; Packham G; Forconi F; Coffey GP; Burger JA; Steele AJ
    Clin Cancer Res; 2017 May; 23(9):2313-2324. PubMed ID: 27697994
    [No Abstract]   [Full Text] [Related]  

  • 18. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics.
    Nadeu F; Royo R; Clot G; Duran-Ferrer M; Navarro A; Martín S; Lu J; Zenz T; Baumann T; Jares P; Puente XS; Martín-Subero JI; Delgado J; Campo E
    Blood; 2021 May; 137(21):2935-2946. PubMed ID: 33211804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological aspects in chronic lymphocytic leukemia (CLL) development.
    García-Muñoz R; Roldan Galiacho V; Llorente L
    Ann Hematol; 2012 Jul; 91(7):981-96. PubMed ID: 22526361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia.
    Stevenson FK; Forconi F; Packham G
    Semin Hematol; 2014 Jul; 51(3):158-67. PubMed ID: 25048780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.